Lakeside Holding Limited (LSH), a U.S.-based leader in cross-border supply chain solutions, has officially expanded into the medical logistics sector with its acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
The acquisition, valued at RMB 4 million (around USD 0.6 million), strengthens Lakeside’s presence in the Chinese pharmaceutical logistics market and is projected to contribute an additional $7 million in annual revenue.
CHECK THIS OUT: Autolus (AUTL) Reports Obe-cel Launch Progress and Strong Cash Position in Q2 2024
Lakeside Holding’s Entry into China’s Growing Medical Logistics Market
Lakeside, which operates under the American Bear Logistics brand, is widely recognized for its cross-border freight services that connect the Asian and U.S. markets.
The acquisition of Hupan Pharmaceutical marks Lakeside’s first entry into medical logistics, a high-demand sector in China. This sector requires specialized transport and handling of pharmaceuticals and medical devices.
Henry Liu, Chairman and CEO of Lakeside Holding, expressed confidence in this strategic move, stating,
“The acquisition of Hupan Pharmaceutical provides Lakeside with a critical foothold in the rapidly growing medical logistics industry in China. This step allows us to deliver top-tier logistics and supply chain solutions tailored to the pharmaceutical sector, broadening our market reach in this emerging field.”
About Hupan Pharmaceutical’s Role and Market Influence in China
Hupan Pharmaceutical, headquartered in Wuhan and established in May 2024, is a comprehensive pharmaceutical distribution and healthcare supply chain service provider in China.
Licensed for drug wholesale, retail, and distribution of third-class medical devices, Hupan Pharmaceutical serves a crucial role in the medical logistics sector.
The company specializes in handling refrigerated pharmaceuticals, peptide hormones, and critical medications, with strong ties to regional providers.
Hupan partners with 15 major Wuhan hospitals, including Sinopharm Group Hubei, a leading Chinese pharmaceutical company.
These partnerships will enable Lakeside to capitalize on an established network, providing seamless logistics solutions for Chinese healthcare institutions.
Strengthening Lakeside’s Asian Market Reach with Medical Logistics Expertise
The acquisition will diversify Lakeside’s revenue streams and strengthen its competitive position in Asia. Lakeside leverages Hupan Pharmaceutical’s expertise to meet the specialized needs of the healthcare sector.
This strategic move supports Lakeside’s growth in Asia, where demand for efficient medical logistics is rapidly increasing.
Lakeside will offer advanced logistics services for healthcare products by integrating Hupan’s medical supply chain expertise. This expansion adds value to its current offerings and meets the unique needs of the medical industry.
Revenue Growth Potential and Shareholder Impact
With this acquisition, Lakeside anticipates a significant boost in revenue, projecting an annual increase of around USD 7 million. This growth potential reinforces Lakeside’s strategy to tap into high-demand markets across Asia.
Expanding into medical logistics, Lakeside enhances its services and strengthens its position in established and emerging markets.
READ ALSO: FDA Clears CEL-SCI’s Multikine Study for Head and Neck Cancer and Aethlon (AEMD) Reports Q1 2024 Results and Advances Cancer and Virus Treatment Trials.
